Biomarker & Intervention Discovery
Vitiligo
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
US DALYs2.23MWHO GHE 2021 · all ages
Global DALYs41.44MWHO GHE 2021 · worldwide
US mortality6,479 deaths/yrWHO GHE 2021
Global mortality92.1K deaths/yrWHO GHE 2021 · worldwide
Spontaneous remissionSpontaneous complete repigmentation extremely rare (<1%); partial spontaneous repigmentation possible in small…
Best-intervention remissionRuxolitinib cream (Opzelura): 29.9% F-VASI75 (75% facial repigmentation) at 24 weeks vs 7.5% vehicle; NB-UVB…
Gap sizeLarge — first topical treatment only approved 2022; NB-UVB is effective but access to specialised units is limited
Primary barrieraccess
Full remission profile →
Remission & chronicity
Spontaneous remission
Spontaneous complete repigmentation extremely rare (<1%); partial spontaneous repigmentation possible in small lesions; progressive without treatment in most patients
Best-intervention remission
Ruxolitinib cream (Opzelura): 29.9% F-VASI75 (75% facial repigmentation) at 24 weeks vs 7.5% vehicle; NB-UVB phototherapy: 75%+ repigmentation in 30-40% of patients at 12 months; excimer laser for localised vitiligo: 75%+ repigmentation in 50-70%; combination ruxolitinib + NB-UVB: superior to either alone
Gap size
Large — first topical treatment only approved 2022; NB-UVB is effective but access to specialised units is limited
Prior to ruxolitinib cream (2022), there was no FDA-approved pharmacotherapy for vitiligo; NB-UVB is effective but requires 2-3x/week sessions for months and is only available in dermatology/phototherapy units; cosmetic dismissal of vitiligo as 'not a medical disease' has delayed research and treatment access
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Vitiligo” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."